|

Evaluation of CMV/EBV-CMI in Haploid HSCT

RECRUITINGSponsored by The First Affiliated Hospital of Soochow University
Actively Recruiting
SponsorThe First Affiliated Hospital of Soochow University
Started2024-08-13
Est. completion2025-07-31
Eligibility
Age16 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06554197

Summary

The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .

Eligibility

Age: 16 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

1. All patients were diagnosed with hemopathy.
2. All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus.
3. All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study.

Exclusion Criteria:

Patients with any conditions not suitable for the trial (investigators' decision).

Conditions4

CancerCytomegalovirus InfectionsEpstein-Barr Virus InfectionsHematopoietic Stem Cell Transplantation

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.